Prism AI is coming!
We’re building a new AI layer designed to turn market data into clearer, more actionable insight.
Prism AI learns from historical and current market behavior to estimate possible outcomes, identify attractive risk/reward setups and derive key trade levels when the opportunity is there.
Already learning. Already testing. Always improving.
See less. Understand more.
Join us at https://t.co/1UBcxDAKEi
@StockMKTNewz The timing is interesting. The valuation will be even more interesting.
If Anthropic comes public this soon, investors may be asked to price in years of AI growth from day one.
The biggest winners may not be the robot makers themselves. Vision, motion control, power electronics and automation software can sell into the entire ecosystem, while humanoid platforms still carry much higher execution and unit-economics risk. That’s where we’d look for the less obvious opportunities.
@StockMKTNewz Heatmaps like this are a good reminder that the index rarely tells the whole story. Sector leadership and dispersion matter just as much as the headline move.
@StockSavvyShay If $AVGO keeps executing anywhere close to this trajectory, today’s weakness could age very badly. $56B in FY26 AI revenue with another major step-up in FY27 is hard to ignore.
@StockSavvyShay The real bottleneck isn’t just GPUs anymore - it’s access to power. But not every MW is equal: AI conversion can require $8–15M/MW plus fiber, cooling and customers.
IREN’s >$4B AI Cloud ARR target, ~85% contracted, shows the upside when execution is there.
@StockSavvyShay This is bigger than just adding capacity. $MU is pairing massive U.S. manufacturing expansion with R&D in Boise, which should help shorten the path from next-gen memory research to production. That matters a lot in the HBM race.
@StockMKTNewz Mixed print for $BABA. The EPS miss hurts, but cloud revenue jumped 45% YoY as AI demand accelerated. The trade-off is heavy spending (capex was up 75%) so growth is strong, but profitability is still under pressure.
$MRNA surged after Moderna and Merck reported positive Phase 3 results for their personalized mRNA cancer vaccine in melanoma.
The market reacted aggressively, with shares jumping sharply as investors repriced the potential of Moderna’s oncology pipeline beyond COVID.
@StockMKTNewz Strong print, but the $4.11 EPS needs context: $1.65 came from tariff refunds. Even excluding that boost, EPS still grew 20% YoY, comps rose 3.8% and digital sales 8.7%. The underlying turnaround looks increasingly real.
Is $APP falling off the radar?
The stock has taken a serious hit, but the underlying business still looks exceptionally strong.
Q2 revenue grew 53% YoY
Net income increased 55%
Adjusted EBITDA rose 58% with an 84% margin
Free cash flow reached $863M
And Q3 guidance still points to roughly $2.1B in revenue with an 83% adjusted EBITDA margin.
That combination of growth, profitability and cash generation is hard to ignore.
The stock got repriced. The business is still executing.
@StockSavvyShay The takeaway is the pricing power.
If Samsung can raise advanced-node prices ~15% with only ~7% foundry share, leading-edge capacity is clearly still tight. That keeps $TSM in a very strong position.
$2,900 is possible, but that’s definitely a bull case.
The thesis would need Sandisk to sustain something close to its long-term targets: "mid to high" teens revenue growth, 80% gross margins and 50% FCF margins. That’s a very different business than the market used to price.
We’d focus more on whether those margins prove durable than on the headline target.
@Mapago9 $APP and $ORCL for us.
$APP: +53% revenue, +58% adj. EBITDA, $863M FCF, with Q3 EBITDA guided to $1.7B . $ORCL: cloud +47%, IaaS +93%, $638B RPO , though the AI buildout pushed FY26 FCF to -$23.7B.
@QC_Capitals If I had to name 3: $RGTI, $QUBT, $QBTS. Great technology potential, but current valuations are still far ahead of revenues while losses remain significant. Execution has to be nearly perfect from here.
Red day so far, but attention isn’t disappearing, it’s rotating.
A few names stand out in this snapshot:
🟢 $OBK — regional banking / financials. Attention acceleration is leading the board here, showing that interest isn’t limited to tech or high-beta names.
🔴 $MRVL — AI infrastructure / semiconductors. Price is down, but attention remains elevated.
🔴 $PWR — power and grid infrastructure. Another reminder that AI demand is not just about chips, but also the physical infrastructure behind them.
🟢 $LDOS — defense and mission technology, showing that attention is broadening beyond pure tech.
🔴 $PRAX — biotech / CNS, where event-driven moves can quickly pull in attention even on a weak tape.
The interesting part isn’t just which stocks are up or down. It’s where market attention is accelerating underneath the surface.